

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8412372

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT	
<b>EFFECTIVE DATE:</b>	04/21/2023	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ASTELLAS PHARMA INC.	10/18/2023
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	VANTAGE BIOSCIENCES LTD.	
<b>Street Address:</b>	78 PALL MALL	
<b>City:</b>	LONDON	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	SW1Y 5ES	
<b>PROPERTY NUMBERS Total: 3</b>		
	<b>Property Type</b>	<b>Number</b>
	Patent Number:	8716470
	Patent Number:	9051283
	Patent Number:	9556160
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(703)739-2815	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	records@clarivate.com	
<b>Correspondent Name:</b>	CPA GLOBAL LIMITED	
<b>Address Line 1:</b>	LIBERATION HOUSE	
<b>Address Line 2:</b>	CASTLE STREET	
<b>Address Line 4:</b>	ST HELIER, JERSEY JE1 1BL	
<b>NAME OF SUBMITTER:</b>	HELEN BIRRELL	
<b>SIGNATURE:</b>	/IPR/AS/NGBVantageBiosciCP2023145/AG3PT/	
<b>DATE SIGNED:</b>	01/31/2024	
<b>Total Attachments: 2</b>		
source=US Assignment#page1.tif		
source=US Assignment#page2.tif		

UNITED STATES OF AMERICA  
**ASSIGNMENT**

WHEREAS, **Astellas Pharma Inc.** ("ASSIGNOR"), a Company organized under the laws of **Japan**, with a place of business at **5-1, Nihonbashi-Honcho 2-chome, Chuo-Ku, Tokyo, Japan 103-8411**, owns the United States Patent(s) (the "Patent(s)") listed on the attached Schedule A; and


WHEREAS, **Vantage Biosciences Ltd.** ("ASSIGNEE"), a Private limited company organized under the laws of **England and Wales**, with a place of business at **78 Pall Mall, London, SW1Y 5ES, UK**, desires to acquire all rights to the Patent(s);

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other valuable consideration, the receipt of which ASSIGNOR acknowledges, ASSIGNOR has sold, assigned, transferred, and set over, and does, by this Assignment, sell, assign, transfer, and set over unto ASSIGNEE, all rights to the Patent(s), including reissues and extensions, to be held and enjoyed by ASSIGNEE, its successors, assigns, and legal representatives, for ASSIGNEE's own use and benefit and for the use and benefit of its successors, assigns, and legal representatives, to the end of the term(s) for which the Patent(s) has/have been granted or may be reissued or extended, as fully and entirely as the Patent(s) would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made; together with all claims for profits and damages by reason of past infringement, with the right to sue for and collect the same for the use and benefit of ASSIGNEE, its successors, assigns, and legal representatives.

This Assignment is deemed to have become effective as from **21 April 2023**

IN WITNESS WHEREOF, ASSIGNOR and ASSIGNEE have caused this Assignment to be executed by its duly authorized officer or representative on the date(s) indicated below.

**Astellas Pharma Inc.**


By: 

Name: **Kosuke Hamai**

Title: **Senior Director, IP Innovation and New Technologies**

Date: **October 18, 2023**

**Vantage Biosciences Ltd.**

By: 

Name: **Alek Safarian**

Title: **Director**

Date: **4 September 2023**

Schedule

Country	Application Number	IP Grant Number
USA	13755822	8716470
USA	14099131	9051283
USA	14671397	9556160